Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 19Recruiting 14Active not recruiting 11Unknown 8Terminated 8Withdrawn 4

Sponsor Class

OTHER 8

Study Type

Interventional 8

Sponsor

Cancer Type

Head & Neck 3Tumor-Agnostic 2Dermatologic 2Gastrointestinal 1

Conditions

Thyroid Neoplasms 3Neoplasms 3Melanoma 2Colorectal Neoplasms 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × Unknown × dabrafenib × Clear all
NCT05876806 2023-11-30

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Seoul St. Mary's Hospital

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT05182931 2023-10-31

I-FIRST

Olivia Newton-John Cancer Research Institute

Phase 2 Unknown
80 enrolled
Head & Neck

Thyroid Neoplasms

NCT02858921 2023-08-30

Neo Trio

Melanoma Institute Australia

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma, Neoplasms

NCT04619316 2023-06-22

ERRITI

University Hospital, Essen

Phase 2 Unknown
70 enrolled
Head & Neck

Thyroid Neoplasms

NCT03668431 2022-06-27

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Massachusetts General Hospital

Phase 2 Unknown
25 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT04554680 2021-03-05

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

National University Hospital, Singapore

Phase 2 Unknown
5 enrolled
Head & Neck

Thyroid Neoplasms

NCT02625337 2017-09-15

IMPemBra

The Netherlands Cancer Institute

Phase 2 Unknown
32 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡